Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

Coral Laboratories Ltd

CORALAB

Coral Laboratories Ltd

CORALAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹289 cr, stock is ranked 2,235
High RiskStock is 3.46x as volatile as Nifty
794.950.51% (+4.05)
794.950.51% (+4.05)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹289 cr, stock is ranked 2,235
High RiskStock is 3.46x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹289 cr, stock is ranked 2,235
High RiskStock is 3.46x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
12.501.63—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.536.560.52%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The Company is engaged in the pharmaceutical business. The Company offers products in various categories like sterile, non sterile, nutraceutical and otc products catering to lifestyle segment.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of -1.27%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.04% to 0.02%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 9.08%, vs industry avg of 15.27%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue79.9198.8496.9496.2476.47100.3681.3885.0590.29118.49
Raw Materialssubtract44.5751.3352.5450.7642.9750.1139.0142.1140.3885.42
Power & Fuel Costsubtract1.451.841.841.851.822.052.553.103.05
Employee Costsubtract4.886.768.579.849.7010.1811.2311.1311.20
Selling & Administrative Expensessubtract4.383.765.016.536.459.329.615.988.39
Operating & Other expensessubtract5.278.839.179.684.229.055.0012.004.57
Depreciation/Amortizationsubtract1.731.561.561.902.011.981.992.181.981.99
Interest & Other Itemssubtract0.240.200.200.170.190.040.140.340.000.04
Taxes & Other Itemssubtract5.018.275.605.291.994.062.811.784.947.89
EPS34.6545.6034.8528.6119.9337.9825.3018.0044.1764.80
DPS3.005.002.002.000.000.000.000.000.002.00
Payout ratio0.090.110.060.070.000.000.000.000.000.03
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2015

Annual report

PDF
FY 2016

Annual report

PDF
FY 2017

Annual report

PDF
FY 2018

Annual report

PDF
FY 2019

Annual report

PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF
FY 2024

Annual report

PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Coral Laboratories Ltd18.341.63—
Sun Pharmaceutical Industries Ltd45.356.470.75%
Cipla Ltd28.514.380.89%
Torrent Pharmaceuticals Ltd68.4516.540.84%

Price Comparison

Compare CORALAB with any stock or ETF
Compare CORALAB with any stock or ETF
CORALAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding71.51%0.00%0.00%0.00%28.49%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.14%0.14%0.14%0.14%0.23%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

CORALAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 20, 2024

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Sep 20, 2024

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Sep 19, 2019

Cash Dividend

Ex DateEx DateSep 18, 2018

Final
Final | Div/Share: ₹2.00

Dividend/Share

₹2.00

Ex DateEx Date

Sep 18, 2018

Cash Dividend

Ex DateEx DateSep 11, 2017

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Sep 11, 2017

Cash Dividend

Ex DateEx DateSep 16, 2016

Final
Final | Div/Share: ₹3.00

Dividend/Share

₹3.00

Ex DateEx Date

Sep 16, 2016

News & Opinions
Earnings
Coral Laboratories standalone net profit rises 6.33% in the September 2024 quarter

Net profit of Coral Laboratories rose 6.33% to Rs 6.38 crore in the quarter ended September 2024 as against Rs 6.00 crore during the previous quarter ended September 2023. Sales rose 39.22% to Rs 32.23 crore in the quarter ended September 2024 as against Rs 23.15 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales32.2323.15 39 OPM %20.2026.57 - PBDT9.047.96 14 PBT8.537.52 13 NP6.386.00 6 Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Coral Laboratories schedules board meeting

Coral Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Coral Laboratories announces board meeting date

Coral Laboratories will hold a meeting of the Board of Directors of the Company on 24 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Coral Laboratories to hold AGM

Coral Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Coral Laboratories AGM scheduled

Coral Laboratories announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Coral Laboratories standalone net profit rises 378.26% in the June 2024 quarter

Net profit of Coral Laboratories rose 378.26% to Rs 8.80 crore in the quarter ended June 2024 as against Rs 1.84 crore during the previous quarter ended June 2023. Sales rose 133.65% to Rs 31.66 crore in the quarter ended June 2024 as against Rs 13.55 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales31.6613.55 134 OPM %33.8912.92 - PBDT12.263.04 303 PBT11.772.49 373 NP8.801.84 378 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Coral Laboratories to conduct board meeting

Coral Laboratories will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live
Corporate
Coral Laboratories to conduct board meeting

Coral Laboratories will hold a meeting of the Board of Directors of the Company on 9 August 2024.Powered by Capital Market - Live

4 months agoCapital Market - Live